NEW YORK, NY, Sept. 18 /PRNewswire-FirstCall/ -- (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova") today announced that it has ceased the relationship with Bridge BioResearch PLC and unconditionally retract the announcement made earlier this month and GENova further announced that Mr. Anders Bogh Jensen, Chief Science Officer of Bridge BioResearch PLC, will not be serving on the GENova's Scientific Advisory Board.
About GENova Biotherapeutics Inc.
GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these drug product candidates to Big Pharmaceutical and Biotechnology companies. Visit GENova online at http://www.genovabio.com/.
Forward Looking Statements
This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.
GENova Biotherapeutics, Inc.
CONTACT: Brian Cook, Windfall Communications LLC, 1-866-797-8703,
info@windfallcommunications.com; Source: Genova Biotherapeutics, Inc.,
1-646-845-1920, info@genovabio.com